Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana

10.1016/S0140-6736(08)60885-5

10.1371/journal.pmed.0050016

10.1371/journal.pmed.0050028

10.1056/NEJMoa1011205

10.1371/journal.pctr.0020027

Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Presented at the 6th IAS Conference on HIV Pathogenesis and Treatment and Prevention, Rome, July 17–20, 2011.

10.1126/science.1193748

Donnell D, Baeten J, Hendrix C, et al. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Presented at the 19th Conference on Retroviruses and Opportunistic Infections, Seattle, March 5–8, 2012.

Buliva E, Vite San Pedro C, Mutanhaurwa R, et al. Bone mineral density (BMD) in a population of healthy HIV-negative young African adults enrolling in a pre-exposure prophylaxis (PrEP) trial in Botswana. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19–22, 2009.

10.1371/journal.pone.0023688

10.1093/infdis/jir188

10.1056/NEJMoa1108524

10.1093/infdis/jiq126

10.1056/NEJMoa1202614

10.1097/QAI.0b013e31817236ab